Sun Pharma to buy Dusa for $230 mln

Last Updated: Thu, Nov 08, 2012 12:11 hrs

Sun Pharmaceutical Industries Ltd said it will acquire U.S. dermatology company Dusa Pharmaceuticals Inc for about $230 million to gain access to its light-based skin treatment platform.

Dusa shareholders will get $8 per share in cash, representing a 38 percent premium to Dusa's Wednesday stock close.

Dusa was advised by Leerink Swann on the deal, the companies said in a joint statement.

More from Sify: